[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Arcutis Biotherapeutics, Inc. Common Stock (ARQT)
ARQT stock surges to a 52-week high driven by strong Q3 earnings and anticipation of an FDA decision. Social media buzz intensifies with positive sentiment and analyst upgrades.
About Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for dermatological conditions.
Arcutis Biotherapeutics, Inc. Common Stock uses the ticker $ARQT for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Arcutis Biotherapeutics, Inc. Common Stock (ARQT) social dominance is up XXXXXX% from the previous week.
Price: $XXXXX
Price 24-Hour Time-Series Raw Data
The stock price has surged to a 52-week high, supported by strong Q3 earnings, positive revenue growth, and anticipation of an FDA decision. High social media engagement and positive sentiment further bolster this upward trend.
24-Hour: -XXXX% 7-Day: -XXXX% 30-Day: XXXXX%
1-Year High: $XXXXX on 2025-12-05
1-Year Low: $XXXXX on 2025-02-11
AltRank: XXXXX
AltRank 24-Hour Time-Series Raw Data
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is currently AltRank #1,199 based on combined combined social and market metrics
Daily Average: XXX
X Week: XXX +407
X Month: XXX +22
1-Year High: XXXXX on 2025-11-07
1-Year Low: XXX on 2025-11-23
Galaxy Score: XXXXX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX -XX
X Month: XX -X
1-Year High: XX on 2025-11-09
1-Year Low: XX on 2025-11-25
Engagements: XXXXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
X Week: XXXXXX -XX%
X Month: XXXXXXX -XXXX%
X Months: XXXXXXXXX -XX%
X Year: XXXXXXXXX -XXXX%
1-Year High: XXXXXXX on 2025-02-21
1-Year Low: XXX on 2025-12-12
Engagements by network (24h): X: XXXXX YouTube: X
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XXX -XX%
X Month: XXX +19%
X Months: XXXXX +69%
X Year: XXXXX -XX%
1-Year High: XXX on 2025-06-28
1-Year Low: XX on 2025-09-14
Mentions by network (24h): X: XXX YouTube: X
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Arcutis Biotherapeutics, Inc. Common Stock (ARQT) in the last XX hours which is down XXXX% from XX in the previous XX hours
Daily Average: XX
X Week: XXX -XX%
X Month: XXX +6.50%
X Months: XXXXX +182%
X Year: XXXXX +146%
1-Year High: XXX on 2025-06-28
1-Year Low: X on 2025-09-21
The most influential creators that mention Arcutis Biotherapeutics, Inc. Common Stock in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @equitydd | X | XXXXX | X | XXX |
| @RebellioMarket | X | XXXXXXX | X | XXX |
| @NightOwlBiotech | X | XXXXX | X | XXX |
| @STvrosb | X | XXX | X | XXX |
| @BiopharmIQ | X | XXXXXX | X | XX |
| @Biotech2k1 | X | XXXXXX | X | XX |
| @TedHZhang | X | XXXXXX | X | XX |
| @seedytx19 | X | XXXXX | X | XX |
| @linhnguyen64143 | X | XX | X | XX |
| @BuyTheUgly | XX | XX | X | XX |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% -XX%
X Month: XX% -XX%
X Months: XX% no change
X Year: XX% +3%
1-Year High: XXX% on 2025-01-31
1-Year Low: XX% on 2025-09-23
Most Supportive Themes:
- Positive Q3 Earnings and Revenue: (30%) Arcutis Biotherapeutics reported a profitable third quarter with revenue significantly exceeding expectations, driven by strong Zoryve sales.
- FDA Decision Catalyst: (25%) An upcoming FDA decision for a topical foam treatment for psoriasis is viewed as a significant catalyst for the company.
- Analyst Upgrades and Price Target Increases: (20%) Multiple analysts have raised their price targets for ARQT, with Goldman Sachs maintaining a Neutral rating and Mizuho raising their target significantly.
Most Critical Themes:
- Neutral Analyst Rating: (15%) Despite positive Q3 results and revenue growth, Goldman Sachs maintains a 'Neutral' rating, suggesting a balanced outlook from this key analyst.
Social Dominance: XXXXXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXX%
X Week: XXXXXX% +0.007%
X Month: XXXX% +0.0029%
X Months: XXXX% +0.0051%
X Year: XXXX% -XXXXXX%
1-Year High: XXXXX% on 2024-12-26
1-Year Low: XXXXXX% on 2025-09-14
Market Dominance: XXXXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-11-24
1-Year Low: XXXXXXX% on 2025-12-12
Market Cap: $XXXXXXXXXXXXX
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX -$5.10%
X Month: $XXXXXXXXXXXXX +$23%
1-Year High: $XXXXXXXXXXXXX on 2025-12-05
1-Year Low: $XXXXXXXXXXXXX on 2025-10-27
Top Arcutis Biotherapeutics, Inc. Common Stock Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$IVVD $CERS $CRVS $ARQT TIME for the Christmas Rally"
X Link @STvrosb 2025-12-11T23:54Z XXX followers, XXX engagements
"Arcutis Biotherapeutics: My Insight on Their Leadership Shake-Up"
YouTube Link @corporatedecoder 2025-12-11T17:41Z 3250 followers, X engagements
"Current top XX holdings. $HROW $CRVS (new) $KURA $NKTR $MDGL $MREO $NKTR $KALA $REGN $ABVX Sold $TARS $ARQT $NUVB"
X Link @FeldtInvesting 2025-12-10T15:51Z XXX followers, XXX engagements
"🚨 $ARQT : Trade Alert Breakout Potential 🚨 📈 Rating: 8.4/10 Potential: +94% A wide rounded daily cup with XX% depth and a clean rim at $XXXXX. The handle is compact and shallow formed above midline with controlled pullback and consistent volume contraction a structurally solid breakout from a long recovery base. 💎 Notes: Multiple resistance levels before the mid-path ATH increase the likelihood of a larger secondary cup forming during continuation. Opportunity Context: I missed the initial breakout price ran too quickly and then missed the pullback as well. I decided to seek an entry"
X Link @AdiPlaut 2025-12-10T12:32Z XXX followers, XX engagements